Early intravenous tranexamic acid administration — Competitive Intelligence Brief

Early intravenous tranexamic acid administration (Early intravenous tranexamic acid administration) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrinolytic agent. Area: Trauma / Hemorrhage / Emergency Medicine.

phase 3 Antifibrinolytic agent Plasminogen / Plasmin Trauma / Hemorrhage / Emergency Medicine Small molecule

Target snapshot

Early intravenous tranexamic acid administration (Early intravenous tranexamic acid administration) — Seoul National University Hospital. Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding in acute trauma and hemorrhage.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Early intravenous tranexamic acid administration TARGET	Early intravenous tranexamic acid administration	Seoul National University Hospital	phase 3	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid Dosage 1	Tranexamic Acid Dosage 1	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Topical tranexamic acid	Topical tranexamic acid	Aswan University Hospital	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid plus standard of care	Tranexamic Acid plus standard of care	Pfizer	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid Injectable Solution	Tranexamic Acid Injectable Solution	Mount Sinai Hospital, Canada	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid Irrigation	Tranexamic Acid Irrigation	University of Wisconsin, Madison	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid (IV)	Tranexamic Acid (IV)	Samsung Medical Center	marketed	Antifibrinolytic agent	Plasminogen / Plasmin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrinolytic agent class)

1. Montefiore Medical Center · 2 drugs in this class
2. Pfizer · 2 drugs in this class
3. Hamilton Health Sciences Corporation · 2 drugs in this class
4. Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class
5. Henry Ford Health System · 1 drug in this class
6. Massachusetts General Hospital · 1 drug in this class
7. NYU Langone Health · 1 drug in this class
8. Mount Sinai Hospital, Canada · 1 drug in this class
9. Dr. Lutfi Kirdar Kartal Training and Research Hospital · 1 drug in this class
10. Carlos A Acosta-Olivo · 1 drug in this class